MX2021001547A - Constructo de acido nucleico recombinante. - Google Patents

Constructo de acido nucleico recombinante.

Info

Publication number
MX2021001547A
MX2021001547A MX2021001547A MX2021001547A MX2021001547A MX 2021001547 A MX2021001547 A MX 2021001547A MX 2021001547 A MX2021001547 A MX 2021001547A MX 2021001547 A MX2021001547 A MX 2021001547A MX 2021001547 A MX2021001547 A MX 2021001547A
Authority
MX
Mexico
Prior art keywords
nucleic acid
utr
acid construct
recombinant nucleic
gene
Prior art date
Application number
MX2021001547A
Other languages
English (en)
Inventor
Oliver Keil
Klaus Giese
Jörg Kaufmann
Original Assignee
Pantherna Therapeutics Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP18188489.1A external-priority patent/EP3608426A1/en
Application filed by Pantherna Therapeutics Gmbh filed Critical Pantherna Therapeutics Gmbh
Publication of MX2021001547A publication Critical patent/MX2021001547A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0069—Oxidoreductases (1.) acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)

Abstract

La presente invención está relacionada con un constructo de ácido nucleico recombinante que comprende en la dirección 5'-> 3' - una 5' UTR, - una región codificante que codifica una molécula efectora, y - una 3' UTR, en donde la 5' UTR se selecciona del grupo que comprende una 5' UTR de un gen o un derivado del mismo que tiene una identidad de nucleótidos de al menos 85%, en donde el gen se selecciona del grupo que consiste en MCP-1, RPL12 s.c., Ang-2, HSP70, H3.3., Galectina-9, GADD34, EDNI, HSP70m5, E-selectina, ICAM-1, IL-6 y vWF.
MX2021001547A 2018-08-10 2019-08-07 Constructo de acido nucleico recombinante. MX2021001547A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP18188489.1A EP3608426A1 (en) 2018-08-10 2018-08-10 Recombinant nucleic acid construct
EP18194023 2018-09-12
EP18248243 2018-12-28
PCT/EP2019/071173 WO2020030672A1 (en) 2018-08-10 2019-08-07 Recombinant nucleic acid construct

Publications (1)

Publication Number Publication Date
MX2021001547A true MX2021001547A (es) 2021-06-23

Family

ID=67544260

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021001547A MX2021001547A (es) 2018-08-10 2019-08-07 Constructo de acido nucleico recombinante.

Country Status (17)

Country Link
US (1) US20210261980A1 (es)
EP (1) EP3833786B1 (es)
JP (1) JP2021533821A (es)
KR (1) KR20210044240A (es)
CN (1) CN112567053A (es)
AU (1) AU2019319035A1 (es)
BR (1) BR112021002333A2 (es)
CA (1) CA3108670A1 (es)
DK (1) DK3833786T3 (es)
ES (1) ES2970185T3 (es)
FI (1) FI3833786T3 (es)
IL (1) IL280157A (es)
MX (1) MX2021001547A (es)
PL (1) PL3833786T3 (es)
SG (1) SG11202100455WA (es)
WO (1) WO2020030672A1 (es)
ZA (1) ZA202100242B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3865122A1 (en) * 2020-02-11 2021-08-18 Pantherna Therapeutics GmbH Lipid composition and use thereof for delivery of a therapeutically active agent to endothelium
WO2022106072A1 (en) 2020-11-18 2022-05-27 Aplicacion Y Suministros Textiles, S.A.U. Textile stone washing process
WO2022110010A1 (zh) * 2020-11-27 2022-06-02 苏州吉玛基因股份有限公司 免疫激活剂、抗原和抗体在制备预防、治疗肿瘤产品中的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000006759A2 (en) * 1998-07-27 2000-02-10 Valentis, Inc. Anti-angiogenesis plasmids and delivery systems, and methods of making and using the same
GB9905498D0 (en) * 1999-03-11 1999-05-05 Glaxo Group Ltd Expression
US7098192B2 (en) * 1999-04-08 2006-08-29 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of STAT3 expression
US8039261B2 (en) * 2000-11-17 2011-10-18 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
KR20120046163A (ko) * 2009-06-15 2012-05-09 바이오카인 테라퓨틱스 리미티드 자가면역, 염증 및 암의 과정을 저해할 수 있는 신규한 케모카인 결합 폴리펩타이드류
CN102712935B (zh) 2009-11-04 2017-04-26 不列颠哥伦比亚大学 含有核酸的脂质粒子及相关的方法
EA201301173A1 (ru) * 2011-04-15 2015-08-31 Дженелюкс Корпорейшн Клональные штаммы аттенуированных вакцинирующих вирусов и способы их использования
DE202015009974U1 (de) * 2014-12-12 2022-02-17 Curevac Ag Artifizielle Nukleinsäuremoleküle für eine verbesserte Proteinexpression
WO2017100551A1 (en) 2015-12-09 2017-06-15 Alexion Pharmaceuticals, Inc. HETEROLOGOUS UTR SEQUENCES FOR ENHANCED mRNA EXPRESSION
WO2017201332A1 (en) * 2016-05-18 2017-11-23 Modernatx, Inc. Polynucleotides encoding acyl-coa dehydrogenase, very long-chain for the treatment of very long-chain acyl-coa dehydrogenase deficiency
US11464847B2 (en) * 2016-12-23 2022-10-11 Curevac Ag Lassa virus vaccine

Also Published As

Publication number Publication date
EP3833786B1 (en) 2023-12-27
JP2021533821A (ja) 2021-12-09
WO2020030672A1 (en) 2020-02-13
BR112021002333A2 (pt) 2021-05-04
CN112567053A (zh) 2021-03-26
FI3833786T3 (fi) 2024-03-15
SG11202100455WA (en) 2021-02-25
CA3108670A1 (en) 2020-02-13
ES2970185T3 (es) 2024-05-27
AU2019319035A1 (en) 2021-02-04
US20210261980A1 (en) 2021-08-26
IL280157A (en) 2021-03-01
KR20210044240A (ko) 2021-04-22
ZA202100242B (en) 2022-05-25
EP3833786A1 (en) 2021-06-16
DK3833786T3 (da) 2024-03-04
PL3833786T3 (pl) 2024-05-06

Similar Documents

Publication Publication Date Title
MX2021001547A (es) Constructo de acido nucleico recombinante.
Hauser et al. Common and biased signaling pathways of the chemokine receptor CCR7 elicited by its ligands CCL19 and CCL21 in leukocytes
Matthias et al. Transcriptional networks in developing and mature B cells
CY1122339T1 (el) Μουτεϊνες δακρυϊκης λιποκαλινης που δεσμευουν il-4 r αλφα
CY1119364T1 (el) Φαρμακοτεχνικες μορφες(ζ)-2-κυανο-3-υδροξυ-βουτ-2-ενοϊκο οξυ-(4'-τριφθορομεθυλοφαινυλο)-αμιδιου με βελτιωμενη σταθεροτητα
JP2023082054A5 (es)
CY1109522T1 (el) Παραγοντες απεικονισης με βαση δικυκλικο πεπτιδιο
CY1107335T1 (el) ΝΕΑ ΠΟΛΥΝΟΥΚΛΕΟΤΙΔΙΑ ΚΑΙ ΠΟΛΥΠΕΠΤΙΔΙΑ ΤΟΥ ΓΟΝΙΔΙΟΥ IFNα-17
DE60232870D1 (de) Neue polynukleotide und polypeptide des erythropoietingens
DE69932599D1 (de) Künstliche chromosomen, die die genetische information für die bildung von rekombinantem virus enthalten
ATE496134T1 (de) Multigene vectoren und methoden für eine erhöhte expression von rekombinanten polypeptiden
NO20052956D0 (no) Defensinprotiner
NO20053018L (no) Pyrazoloquinoliner med immunmodulerende aktivitet.
BR112018013246A2 (pt) rótulo de peptídeo e proteína rotulada incluindo o mesmo
DE60213221D1 (de) Neuartige polynukleotide und polypeptide des ifnalpha-21 gens
ATE532861T1 (de) Expressionsvektor
WO2021160758A3 (en) Recombinant nucleic acid construct and use thereof
Arnold et al. Genomic and functional analysis of the host response to acute simian varicella infection in the lung
Ng et al. Tissue-specific and interferon-inducible expression of non-functional ACE2 through endogenous retrovirus co-option
AR040521A1 (es) Gen sisntetico que codifica al factor estimulante de colonias de granulocitos humano para la expresion e. coli
DE602004018349D1 (de) MODIFIZIERTE cDNA FÜR HOHE EXPRESSIONSNIVEAUS VON FAKTOR VIII UND DESSEN DERIVATEN
EA202092963A1 (ru) Новый белок с противовоспалительными свойствами
DE602005018369D1 (de) Neue proteine, z.b. zur verwendung für die in-vitro-isolierung und prävention von legionella pneumophila-infektionen
Salzberg Assembly of a pan-genome from deep sequencing of 910 humans of African descent
Heufler et al. Cybr, CYTIP or CASP: An attempt to pinpoint a molecule's functions and names